269 related articles for article (PubMed ID: 23170306)
41. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.
Buchen S; Ngampolo D; Melton RG; Hasan C; Zoubek A; Henze G; Bode U; Fleischhack G
Br J Cancer; 2005 Feb; 92(3):480-7. PubMed ID: 15668713
[TBL] [Abstract][Full Text] [Related]
42. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys.
Adamson PC; Balis FM; McCully CL; Godwin KS; Poplack DG
J Clin Oncol; 1992 Aug; 10(8):1359-64. PubMed ID: 1634927
[TBL] [Abstract][Full Text] [Related]
43. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
44. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
45. Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
Schaff LR; Lobbous M; Carlow D; Schofield R; Gavrilovic IT; Miller AM; Stone JB; Piotrowski AF; Sener U; Skakodub A; Acosta EP; Ryan KJ; Mellinghoff IK; DeAngelis LM; Nabors LB; Grommes C
BMC Cancer; 2022 Jan; 22(1):60. PubMed ID: 35027038
[TBL] [Abstract][Full Text] [Related]
46. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
[No Abstract] [Full Text] [Related]
47. Concepts in use of high-dose methotrexate therapy.
Treon SP; Chabner BA
Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
[TBL] [Abstract][Full Text] [Related]
48. Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients.
Medrano C; Oberic L; Puisset F; Recher C; Larrieu-Ciron D; Ysebaert L; Protin C; Picard M; Perriat S; Chatelut E; Bertoli S; Huguet F; Tavitian S; Faguer S
Leuk Lymphoma; 2021 Apr; 62(4):846-853. PubMed ID: 33179543
[TBL] [Abstract][Full Text] [Related]
49. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
50. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Widemann BC
Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
[No Abstract] [Full Text] [Related]
51. Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate.
Schafer ES; Bernhardt MB; Reichert KE; Haworth TE; Shah MD
Am J Hematol; 2018 Feb; 93(2):E40-E42. PubMed ID: 29119597
[No Abstract] [Full Text] [Related]
52. Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
Krackhardt A; Schwartz S; Korfel A; Thiel E
Leuk Lymphoma; 1999 Nov; 35(5-6):631-5. PubMed ID: 10609804
[TBL] [Abstract][Full Text] [Related]
53. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
Widemann BC; Balis FM; Shalabi A; Boron M; O'Brien M; Cole DE; Jayaprakash N; Ivy P; Castle V; Muraszko K; Moertel CL; Trueworthy R; Hermann RC; Moussa A; Hinton S; Reaman G; Poplack D; Adamson PC
J Natl Cancer Inst; 2004 Oct; 96(20):1557-9. PubMed ID: 15494606
[TBL] [Abstract][Full Text] [Related]
54. A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?
Domingo-González A; Osorio S; Landete E; Monsalvo S; Díez-Martín JL
J Oncol Pharm Pract; 2021 Apr; 27(3):734-738. PubMed ID: 32731844
[TBL] [Abstract][Full Text] [Related]
55. Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure.
Hum M; Kamen BA
Pediatr Hematol Oncol; 1995; 12(6):521-4. PubMed ID: 8588996
[No Abstract] [Full Text] [Related]
56. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
57. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
58. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
59. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
[TBL] [Abstract][Full Text] [Related]
60. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
Widemann BC
Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
